|
|
|
|
|
|
|
|
"...women with a BSA>2 m(2) on paclitaxel dosed by ABW do not experience excess toxicity in comparison to women on paclitaxel capped at a maximum BSA or women in published trials of adjuvant P/C. Empiric dose reduction is unnecessary and may result in suboptimal treatment...."
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.